Biotech Losers: Actinium Pharmaceuticals (NYSEMKT:ATNM), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), GenVec (NASDAQ:GNVC), Genetic Technologies Limited (NASDAQ:GENE), Corium International (NASDAQ:CORI)


Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company’s Iomab-B drug candidate currently undergoing final preparations to start the pivotal Phase 3 trial in mid-2015. On Tuesday shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) closed at $5.54.

EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), announced that it has commenced an underwritten public offering of shares of its common stock. EPIRUS intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) in last trading activity moved down -11.32% to close at $5.72. Company weekly performance is -23.43% while its quarterly performance stands at 14.40%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is -67.13% away from its 52 week high.

Roth Capital set a $8.00 target price on shares of GenVec (NASDAQ:GNVC) stock in a research note issued on Friday. The firm currently has a a “buy” rating on the stock. Roth Capital’s price objective would suggest a potential upside of 132.56% from the stock’s previous close. On last trading day GenVec, Inc. (NASDAQ:GNVC) moved down -6.01% to close at $3.44. Its volatility for the week is 9.77% while volatility for the month is 12.10%. GNVC’s sales growth for past 5 years was -24.50% and its EPS growth for past 5 years was 24.60%. GenVec, Inc. (NASDAQ:GNVC) monthly performance is 68.63%.

On 21st January Genetic Technologies Limited (NASDAQ: GENE) announced that it has entered into a A$24 million Standby Equity Placement Facility Agreement (the “Facility” or “Agreement”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment and advisory firm, to strengthen the Company’s funding position. Genetic Technologies Limited (NASDAQ:GENE) has 1.50% insider ownership while its institutional ownership stands at 2.70%. In last trading activity company’s stock closed at $1.27.

On last trading day Corium International, Inc. (NASDAQ:CORI) moved down -5.56% to close at $6.63. Its volatility for the week is 6.31% while volatility for the month is 6.52%. Corium International, Inc. (NASDAQ:CORI) monthly performance is 2.95%.


Leave a Reply

Your email address will not be published. Required fields are marked *